Introduction: Obesity and type 2 diabetes mellitus (T2DM) pose significant health challenges, necessitating innovative interventions. This study aims to explore the efficacy of a novel swallowable balloon process in addressing these dual burdens. Methodology: To evaluate weight loss, diabetes remission, and adverse events (AEs) in 150 patients with a body mass index of 30–40 kg/m². The swallow balloon was inserted, and outcomes were assessed over a 6-month follow-up period. Results: The swallowable balloon process demonstrated consistent and significant (p < 0.001) weight loss, with mean percentage total weight loss (%TWL) ranging from 6.8 to 14.6% and mean percentage excess weight loss (% EWL) ranging from 15.5 to 32.8% over the 6-month follow-up period. Remarkably, diabetes remission rates were notable at 30% in 3 months and an impressive 67% in 6 months post-balloon insertion. However, AEs, particularly nausea and vomiting extending beyond one week, occurred in 12% of participants, leading to hospital admission, highlighting the importance of careful monitoring and management. Additionally, nausea and vomiting occurred in 46.6% and 40.6% of participants, respectively, without major complications. Conclusion: The swallowable balloon process demonstrates promising outcomes in weight loss and diabetes remission over the end of period. AEs require careful consideration, emphasizing the need for ongoing research to optimize safety and efficacy. This intervention offers a nonsurgical approach for individuals with obesity and T2DM, marking a significant step toward addressing these interconnected health challenges.